Recurrence Rate and Associated Factors of Primary Fallopian Tube Carcinoma in the South of Vietnam.

IF 1.4 Q3 OBSTETRICS & GYNECOLOGY Gynecology and Minimally Invasive Therapy-GMIT Pub Date : 2024-09-07 eCollection Date: 2024-10-01 DOI:10.4103/gmit.gmit_110_23
Tuan Vo, Duy Nguyen, Thang Ho, Hoang Tran, Dat Nguyen, Thuong Bui, Thinh Cao, Brian Vo
{"title":"Recurrence Rate and Associated Factors of Primary Fallopian Tube Carcinoma in the South of Vietnam.","authors":"Tuan Vo, Duy Nguyen, Thang Ho, Hoang Tran, Dat Nguyen, Thuong Bui, Thinh Cao, Brian Vo","doi":"10.4103/gmit.gmit_110_23","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>This study aimed to determine the recurrence rate and related risk factors of primary fallopian tube cancer (PFTC).</p><p><strong>Materials and methods: </strong>We conducted a retrospective study of 47 patients with histopathological diagnosis of PFTC treated at Tu Du Hospital between January 1, 2015, and July 31, 2022. The cumulative recurrence rate was estimated using the life table method, and recurrence-associated factors were determined using the Log-rank test and Cox proportional hazard model.</p><p><strong>Results: </strong>The median follow-up period was 40 months (range, 7-96 months). Eight patients (17.0%) experienced recurrence. The cumulative recurrence rate of PFTC patients at 12 months was 4.4% (95% confidence interval [95% CI]: 1.12-16.45), at 24 months was 9.1% (95% CI: 3.52-22.5), at 36 months was 14.9% (95% CI: 6.92-30.41), at 48 months was 19.3% (95% CI: 9.35-37.24), and at 60 months was 25.7% (95% CI: 12.68-47.88). A higher recurrence rate was significantly associated with elevated pretreatment CA 125 level (<35 U/mL vs. ≥35 U/mL, hazards ratio [HR] = 36.9, 95% CI: 1.47-921.37), advanced FIGO stages (Stage I-II vs. stages III, HR = 6.61, 95% CI: 1.18-36.93), and suboptimal debulking surgery (residual disease ≤1 cm vs. residual disease >1 cm, HR = 7.52, 95% CI: 1.47-38.49).</p><p><strong>Conclusion: </strong>The overall recurrence rate of PFTC patients in Southern Vietnam was 17.0%. Appropriate follow-up strategies for patients with high-risk factors are needed for early detection and management of recurrence.</p>","PeriodicalId":45272,"journal":{"name":"Gynecology and Minimally Invasive Therapy-GMIT","volume":"13 4","pages":"247-252"},"PeriodicalIF":1.4000,"publicationDate":"2024-09-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11626892/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Gynecology and Minimally Invasive Therapy-GMIT","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4103/gmit.gmit_110_23","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/10/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"OBSTETRICS & GYNECOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Objectives: This study aimed to determine the recurrence rate and related risk factors of primary fallopian tube cancer (PFTC).

Materials and methods: We conducted a retrospective study of 47 patients with histopathological diagnosis of PFTC treated at Tu Du Hospital between January 1, 2015, and July 31, 2022. The cumulative recurrence rate was estimated using the life table method, and recurrence-associated factors were determined using the Log-rank test and Cox proportional hazard model.

Results: The median follow-up period was 40 months (range, 7-96 months). Eight patients (17.0%) experienced recurrence. The cumulative recurrence rate of PFTC patients at 12 months was 4.4% (95% confidence interval [95% CI]: 1.12-16.45), at 24 months was 9.1% (95% CI: 3.52-22.5), at 36 months was 14.9% (95% CI: 6.92-30.41), at 48 months was 19.3% (95% CI: 9.35-37.24), and at 60 months was 25.7% (95% CI: 12.68-47.88). A higher recurrence rate was significantly associated with elevated pretreatment CA 125 level (<35 U/mL vs. ≥35 U/mL, hazards ratio [HR] = 36.9, 95% CI: 1.47-921.37), advanced FIGO stages (Stage I-II vs. stages III, HR = 6.61, 95% CI: 1.18-36.93), and suboptimal debulking surgery (residual disease ≤1 cm vs. residual disease >1 cm, HR = 7.52, 95% CI: 1.47-38.49).

Conclusion: The overall recurrence rate of PFTC patients in Southern Vietnam was 17.0%. Appropriate follow-up strategies for patients with high-risk factors are needed for early detection and management of recurrence.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
越南南部地区原发性输卵管癌复发率及相关因素分析。
目的:探讨原发性输卵管癌(PFTC)的复发率及相关危险因素。材料与方法:我们对2015年1月1日至2022年7月31日在杜都医院治疗的47例经组织病理学诊断为PFTC的患者进行回顾性研究。使用生命表法估计累积复发率,使用Log-rank检验和Cox比例风险模型确定复发相关因素。结果:中位随访时间为40个月(范围7-96个月)。8例(17.0%)复发。PFTC患者12个月时的累积复发率为4.4%(95%可信区间[95% CI]: 1.12-16.45), 24个月时为9.1% (95% CI: 3.52-22.5), 36个月时为14.9% (95% CI: 6.92-30.41), 48个月时为19.3% (95% CI: 9.35-37.24), 60个月时为25.7% (95% CI: 12.68-47.88)。高复发率与预处理CA 125水平升高(1 cm, HR = 7.52, 95% CI: 1.47 ~ 38.49)显著相关。结论:越南南部PFTC患者的总复发率为17.0%。有高危因素的患者需要适当的随访策略,以便及早发现和管理复发。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
2.00
自引率
16.70%
发文量
98
审稿时长
52 weeks
期刊最新文献
Laparoscopic Cesarean Scar Defect Repair in Six Steps. Laparoscopic Cornuostomy: A Conservative Surgical Approach to Interstitial Pregnancy - A Case Report. Spontaneous Parasitic Pedunculated Myoma Presenting the Absence of Uterine Smooth Muscle Cells in the Stalk - A Case Report. Successful Microablative Fractional Carbon Dioxide Laser Therapy for Vulvar Lichen Sclerosus: A Case Report and Mini-review. The Art of Managing Infertile Patients with Adenomyosis.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1